Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions.

Schwartz BG, Jackson G, Stecher VJ, Campoli-Richards DM, Kloner RA.

Am J Med. 2013 Mar;126(3):192-9. doi: 10.1016/j.amjmed.2012.08.015. Review.

PMID:
23410557
2.

The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.

Chrysant SG, Chrysant GS.

J Clin Hypertens (Greenwich). 2012 Sep;14(9):644-9. doi: 10.1111/j.1751-7176.2012.00669.x. Epub 2012 Jun 7. Review.

3.

Cardiac uses of phosphodiesterase-5 inhibitors.

Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA.

J Am Coll Cardiol. 2012 Jan 3;59(1):9-15. doi: 10.1016/j.jacc.2011.07.051. Review.

4.

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

Chrysant SG.

Curr Hypertens Rep. 2013 Oct;15(5):475-83. doi: 10.1007/s11906-013-0377-9. Review.

PMID:
23917809
5.
6.

Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.

Nguyen H, Amanullah AM.

Rev Cardiovasc Med. 2014;15(2):158-67. Review.

PMID:
25051133
7.

Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.

Higashi Y, Chayama K, Yoshizumi M.

Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):133-48. Review.

PMID:
15853700
8.

Beneficial actions of nitrates in cardiovascular disease.

Abrams J.

Am J Cardiol. 1996 May 30;77(13):31C-7C. Review.

PMID:
8638524
9.

Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease.

Lyons D.

Int J Cardiol. 1997 Dec 31;62 Suppl 2:S101-9. Review.

PMID:
9488201
10.

Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.

Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.

Cardiol Rev. 2007 Mar-Apr;15(2):76-86. Review.

PMID:
17303994
11.

Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Pofi R, Gianfrilli D, Badagliacca R, Di Dato C, Venneri MA, Giannetta E.

J Endocrinol Invest. 2016 Feb;39(2):131-42. doi: 10.1007/s40618-015-0339-y. Epub 2015 Jul 5. Review.

PMID:
26142740
12.

Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation.

Simonsen U, Rodriguez-Rodriguez R, Dalsgaard T, Buus NH, Stankevicius E.

Pharmacol Rep. 2009 Jan-Feb;61(1):105-15. Review.

13.

Exercise and the nitric oxide vasodilator system.

Maiorana A, O'Driscoll G, Taylor R, Green D.

Sports Med. 2003;33(14):1013-35. Review.

PMID:
14599231
14.

Vasoprotection by nitric oxide: mechanisms and therapeutic potential.

Gewaltig MT, Kojda G.

Cardiovasc Res. 2002 Aug 1;55(2):250-60. Review.

PMID:
12123764
15.

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.

Corinaldesi C, Di Luigi L, Lenzi A, Crescioli C.

J Endocrinol Invest. 2016 Feb;39(2):143-51. doi: 10.1007/s40618-015-0340-5. Epub 2015 Jun 28. Review.

16.

Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.

Ganz P.

Am J Cardiol. 2005 Dec 26;96(12B):8M-12M. Epub 2005 Jul 27. Review.

PMID:
16387559
17.
18.

Possibilities and perspectives of pharmacotherapy for endothelial protection.

Lüscher TF.

Curr Opin Nephrol Hypertens. 1993 Jan;2(1):129-36. Review.

PMID:
7922159
19.

Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease.

Noll G, Wenzel RR, Lüscher TF.

Mol Cell Biochem. 1996 Apr 12-26;157(1-2):259-67. Review.

PMID:
8739256
20.

Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease.

Giles TD.

J Clin Hypertens (Greenwich). 2006 Dec;8(12 Suppl 4):2-16. Review.

Supplemental Content

Support Center